Literature DB >> 12670406

Molecular and immunological basis of X-linked lymphoproliferative disease.

Sylvain Latour1, André Veillette.   

Abstract

X-linked lymphoproliferative (XLP) disease is a human immune dysfunction characterized primarily by an inappropriate response to Epstein-Barr virus infection. In 1998, it was discovered that XLP is caused by inactivating mutations in the SAP/SH2D1A/DSHP gene. This gene codes for an immune cell-specific polypeptide termed SAP (SLAM-associated protein) that is composed almost exclusively of an Src homology 2 (SH2) domain. By way of its SH2 domain, SAP interacts with tyrosine-based motifs located in the cytoplasmic region of members of the SLAM (signaling lymphocyte activation molecule) family of receptors. Recent findings indicate that SAP is required for the function of SLAM-related receptors, as a consequence of its capacity to promote the recruitment and activation of the Src-related protein tyrosine kinase FynT, thereby allowing SLAM receptor-mediated protein tyrosine phosphorylation signals in immune cells. Functional and genetic analyses suggest that the phenotype associated with XLP is caused in large part by defects in the functions of SLAM-related receptors due to SAP deficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670406     DOI: 10.1034/j.1600-065x.2003.00023.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  16 in total

1.  Defective B cell responses in the absence of SH2D1A.

Authors:  Massimo Morra; Robert A Barrington; Ana C Abadia-Molina; Susumo Okamoto; Aimee Julien; Charles Gullo; Anuj Kalsy; Matthew J Edwards; Gang Chen; Rosanne Spolski; Warren J Leonard; Brigitte T Huber; Persephone Borrow; Christine A Biron; Abhay R Satoskar; Michael C Carroll; Cox Terhorst
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-17       Impact factor: 11.205

2.  Lck regulates the threshold of activation in primary T cells, while both Lck and Fyn contribute to the magnitude of the extracellular signal-related kinase response.

Authors:  Matthew Lovatt; Andrew Filby; Valentino Parravicini; Guy Werlen; Ed Palmer; Rose Zamoyska
Journal:  Mol Cell Biol       Date:  2006-09-11       Impact factor: 4.272

Review 3.  Immunity to microbes: lessons from primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Antonio Coutinho
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

4.  Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Silvia Pizzi; Tiziana D'Adda; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2005-10-22       Impact factor: 4.064

5.  Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene.

Authors:  B Tóth; B Soltész; E Gyimesi; G Csorba; Á Veres; Á Lányi; G Kovács; L Maródi; M Erdős
Journal:  J Clin Immunol       Date:  2014-12-10       Impact factor: 8.317

6.  X-linked lymphoproliferative disease presenting as pancytopenia in a 10-month-old boy.

Authors:  S Nicole Chadha; David Amrol
Journal:  Case Rep Med       Date:  2010-06-21

7.  Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis.

Authors:  Hal B. Jenson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

8.  SAP enables T cells to help B cells by a mechanism distinct from Th cell programming or CD40 ligand regulation.

Authors:  Cris Kamperschroer; Deborah M Roberts; Yongqing Zhang; Nan-Ping Weng; Susan L Swain
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 9.  X-linked immunodeficiencies.

Authors:  Hans D Ochs; Luigi D Notarangelo
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

10.  Normal development and activation but altered cytokine production of Fyn-deficient CD4+ T cells.

Authors:  Alusha A Mamchak; Brandon M Sullivan; Baidong Hou; Linda M Lee; Julia K Gilden; Matthew F Krummel; Richard M Locksley; Anthony L DeFranco
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.